Unmanipulated haploidentical versus matched unrelated donor allogeneic stem cell transplantation in adult patients with acute myelogenous leukemia in first remission: a retrospective pair-matched comparative study of the Beijing approach with the EBMT database

Abstract excerpt

For adult patients with intermediate-risk acute myelogenous leukemia (AML) in first complete remission (CR1), allogeneic stem cell transplantation (allo-SCT) has been demonstrated to be the best therapeutic option. The ideal donor is a HLA-genoidentical sibling. In the absence of a genoidentical donor, a HLA 10/10 or 8/8 matched unrelated donor (URD) is presently considered to be the best choice, taking advantage...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acute Myeloid Leukemia Research
• Share to Chronic Myeloid Leukemia Treatments